Title : AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations.

Pub. Date : 2018 May 19

PMID : 29783721






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations. gemcitabine tumor protein p53 Homo sapiens
2 Moreover, the combination of AZD1775 with olaparib or gemcitabine is synergistic in cells with mutant p53 and constitutes a new approach that should be considered in the treatment of advanced and recurrent gynecologic cancer. gemcitabine tumor protein p53 Homo sapiens